Ataxia with giant axonopathy in Acbd5 -deficient mice halted by adeno-associated virus gene therapy
Brain · 2024
DOI: 10.1093/brain/awad407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2024. Verfasst von Luis Granadeiro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neurolipid Biology, Instituto de Investigação e Inovação em Saúde da Universidade do Porto - i3S and Instituto de Biologia Molecular e Celular - IBMC…. Hauptthemen laut MEDLINE: Fatty Acids, Adrenoleukodystrophy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: Fundação para a Ciência e a Tecnologia-FCT, National Funds.
Abstract (Originalsprache)
Acyl-CoA binding domain containing 5 (ACBD5) is a critical player in handling very long chain fatty acids (VLCFA) en route for peroxisomal β-oxidation. Mutations in ACBD5 lead to the accumulation of VLCFA and patients present retinal dystrophy, ataxia, psychomotor delay and a severe leukodystrophy. Using CRISPR/Cas9, we generated and characterized an Acbd5 Gly357* mutant allele. Gly357* mutant mice recapitulated key features of the human disorder, including reduced survival, impaired locomotion and reflexes, loss of photoreceptors, and demyelination. The ataxic presentation of Gly357* mice involved the loss of cerebellar Purkinje cells and a giant axonopathy throughout the CNS. Lipidomic studies provided evidence for the extensive lipid dysregulation caused by VLCFA accumulation. Following a proteomic survey, functional studies in neurons treated with VLCFA unravelled a deregulated cytoskeleton with reduced actin dynamics and increased neuronal filopodia. We also show that an adeno-associated virus-mediated gene delivery ameliorated the gait phenotypes and the giant axonopathy, also improving myelination and astrocyte reactivity. Collectively, we established a mouse model with significance for VLCFA-related disorders. The development of relevant neuropathological outcomes enabled the understanding of mechanisms modulated by VLCFA and the evaluation of the efficacy of preclinical therapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurolipid Biology, Instituto de Investigação e Inovação em Saúde da Universidade do Porto - i3S and Instituto de Biologia Molecular e Celular - IBMC, 4200-135 Porto, Portugal.
- Graduate Program in Molecular and Cell Biology, Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Universidade do Porto, 4050-313 Porto, Portugal.
- Animal Facility, Instituto de Investigação e Inovação em Saúde da Universidade do Porto - i3S, 4200-135 Porto, Portugal.
ORCID-Profile: Pedro Brites
Förderung
- Fundação para a Ciência e a Tecnologia-FCT
- National Funds
Zitieren
APA
Granadeiro, L., Zarralanga, V. E., Rosa, R., Franquinho, F., Lamas, S., & Brites, P. (2024). Ataxia with giant axonopathy in Acbd5 -deficient mice halted by adeno-associated virus gene therapy. Brain. https://doi.org/10.1093/brain/awad407
Vancouver
Granadeiro L, Zarralanga VE, Rosa R, Franquinho F, Lamas S, Brites P. Ataxia with giant axonopathy in Acbd5 -deficient mice halted by adeno-associated virus gene therapy. Brain. 2024. doi:10.1093/brain/awad407
BibTeX
@article{Granadeiro2024,
author = {Granadeiro, Luis and Zarralanga, Violeta Enríquez and Rosa, Ricardo and Franquinho, Filipa and Lamas, Sofia and Brites, Pedro},
title = {Ataxia with giant axonopathy in Acbd5 -deficient mice halted by adeno-associated virus gene therapy},
journal = {Brain},
year = {2024},
doi = {10.1093/brain/awad407}
}
EUVIMED